Simple Summary Alterations in glycosylation are frequently observed in cancer cells.
Different strategies have been proposed to increase drug delivery to the tumor site in order …

Antibody–drug conjugates (ADC) utilizing the targeting properties of antibodies and
therapeutic effects of drugs have emerged a rapid development in recent years. However …

Introduction Despite advances in the treatment of acute myeloid leukemia (AML), long-term
survival remains low. In 1994, it was proposed that leukemic stem cells (LSCs) played a key …

A drug conjugate consists of a cytotoxic drug bound via a linker to a targeted ligand,
allowing the targeted delivery of the drug to one or more tumor sites. This approach …

The isocitrate dehydrogenase enzyme, catalyzing isocitrate conversion to α-ketoglutarate
(αKG) in both the cell cytoplasm and mitochondria, contributes to the production of …

Acute myeloid leukemia (AML) is one of the most common forms of leukemia. Despite
advances in the management of such malignancies and the progress of novel therapies …

Notoriously known for their capacity to reconstitute hematological malignancies in vivo,
leukemic stem cells (LSCs) represent key drivers of therapeutic resistance and disease …

Antibody-drug conjugates (ADCs) are one of the most rapidly expanding classes of
oncology therapeutics. Till now, 11 ADCs have been approved by USFDA, with the first ADC …

Background Interleukin-1 receptor accessory protein (IL-1RAP) is one of the most promising
therapeutic targets proposed for myeloid leukemia. Antibodies (Abs) specific to IL-1RAP …

Background Gemtuzumab‐ozogamycin (GO) is approved in combination with high‐dose
chemotherapy for treatment‐naïve low‐and intermediate‐risk acute myeloid leukemia …